Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)

A legfontosabb adatok

Ki végzi
Hangzhou Endonom Medtech Co., Ltd.
Hol
Kína29 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
120 fő vett részt
Kezdés
2020. dec. 25.
Várható befejezés
2026. dec. 25.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • WeFlow-Tbranch Stent Graft System
A regiszteradat frissítve
2024. április 30.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients aged 18 to 80 years old, no gender limitation
  • Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol
  • Diagnosed as Stanford type B aortic dissection and needed reconstruction of the left subclavian artery
  • The diameter of the proximal anchoring area (the aorta at the posterior edge of the left common carotid artery) range: 18~42mm
  • The length of the proximal anchoring area (the distance from the rear edge of the left common carotid artery opening to the first breach) ≥15mm
  • The distance between the left common carotid artery and the left subclavian artery ≥5mm
  • The distance between the left vertebral artery and the opening of the left subclavian artery is ≥15mm, the diameter of the starting part of the left subclavian artery is 6~20mm
  • With proper femoral artery, iliac artery, and brachial artery access, endovascular treatment of the aorta can be performed

Ki nem vehet részt

  • Participated in clinical trials of other drugs or devices during the same period
  • Contraindications to antiplatelet drugs and anticoagulants
  • The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.), and the postoperative drug treatment plan is therefore affected
  • Allergic to contrast agents, anesthetics, patches, and delivery materials
  • History of myocardial infarction, TIA or cerebral infarction within the past 3 months
  • Life expectancy is less than 12 months (such as advanced malignant tumors)
  • Acute systemic infection
  • Severe liver, kidney, lung, and heart function abnormalities before surgery [Serum creatinine exceeds 2 times the upper limit of normal; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 5 times the upper limit of normal; Serum total bilirubin (STB) more than 2 times the upper limit of normal; Left ventricular ejection fraction is lower than normal by cardiac color Doppler ultrasound examination]
  • Pregnant, breastfeeding or cannot contraception during the trial period
  • Cannot tolerate anesthesia
  • True/false thoracic aortic aneurysm
  • Severe stenosis or calcification in the anchoring area at the proximal end of the stent, easily lead to the stent graft difficult adherent
  • Investigator judged that not suitable for interventional treatment

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective, multiple center study to evaluate the safety and effectiveness of WeFlow-Tbranch single embedded branch thoracic aorta stent graft system manufactured by EndoNom Medtech (Hangzhou) Co., Ltd.

A vizsgálat csoportja

  • WeFlow-Tbranch Stent Graft SystemA vizsgált kezelés

    Participants will be treated with WeFlow-Tbranch Stent Graft System

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. április 30.